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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Prednisolone or Pentoxifylline for Alcoholic Hepatitis
To the Editor: In their article on the Steroids or 
Pentoxifylline for Alcoholic Hepatitis (STOPAH) 
trial, Thursz et al. (April 23 issue)1 explain their 
choice not to select patients on the basis of liver-
biopsy results because such procedures are “un-
common” in this group of patients and the goal 
was to replicate the typical conditions of clinical 
practice. However, by basing their diagnosis on 
clinical factors, they misclassified a considerable 
number of patients, given that a Maddrey’s dis-
criminant function (MDF) score of 32 or more 
alone for diagnosis lacks specificity.2 In a pro-
spective study conducted in our center between 
2005 and 2014, we evaluated 114 patients with a 
similar clinical definition of severe alcoholic 
hepatitis and an MDF score of 32 or more. All the 
patients underwent transjugular liver biopsy 
within 72 hours after hospital admission.3 Of 
these patients, 38 (33%) did not have histologic 
features of severe alcoholic hepatitis and were 
thus misdiagnosed on clinical grounds. There-
fore, the authors incorporated a 30% chance of 
erroneous diagnosis and probably included pa-
tients who were unlikely to benefit from pred-
nisolone treatment. In future trials involving 
patients with alcoholic hepatitis, histologic con-
firmation should be pursued, as recommended 
by international guidelines.4,5
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To the Editor: As a matter of practical necessi-
ty, interventional trials often test a reasonable 
dose and duration of a drug regimen and so leave 
unanswered the most effective dose for the con-
dition under investigation. Thursz and colleagues 
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appropriately conclude that prednisolone as used 
in their study may have had a modest but fleeting 
survival benefit in patients with alcoholic hepati-
tis. The rate of death was decreased by a border-
line-significant 28% at the primary 28-day end 
point; after adjustment in the multivariate analy-
sis, the reduction was a significant 39%. In stark 
contrast, this survival benefit was completely lost 
by day 90, indicating that mortality among pred-
nisolone recipients (predominantly attributed to 
liver injury) had caught up with the control rate 
during the 2 months after prednisolone was dis-
continued.1,2 Since tapering doses are not de-
scribed, a speculative concern is that patients 
may have been harmed by an inflammatory re-
constitution reaction to the abrupt withdrawal of 
prednisolone.2-5 Accordingly, it may be prema-
ture to abandon the use of glucocorticoids for 
severe alcoholic hepatitis just yet, given the early 
survival benefit in the face of a clinically plausi-
ble explanation for the catch-up mortality.
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The authors reply: The role of liver biopsy in 
the diagnosis of alcoholic hepatitis remains con-
troversial, with the guidelines of the American 
Association for the Study of Liver Diseases being 
less didactic regarding its necessity.1 It is fair to 
state that the routine use of biopsy is uncom-
mon, as indicated in a recent clinician survey.2 
The diagnosis of alcoholic hepatitis should never 
rely simply on an arithmetic calculation of a dis-
criminant function. Cardinal to the clinical diag-
nosis of alcoholic hepatitis in our study was the 
recognition of a minimal threshold of serum bil-
irubin (>80 µmol per liter), a recent onset of 
jaundice (<3 months), and a clear recent history 
of alcohol excess (≤2 months). The abstract cited 
by Verbeke et al. describes patients with a dis-
criminant function of 32 or more without refer-
ence to these clinical criteria.3 Their results seem 
to be at variance with a previous report from the 
same group, which describes patients presenting 
with alcoholic acute-on-chronic liver failure with 
a recent onset of hyperbilirubinemia (bilirubin 
level, >85 µmol per liter).4 In that study, 96% of 
patients had some features of alcoholic steato-
hepatitis.
We have recently reported an analysis of liver-
biopsy samples that were obtained from the pa-
tients in our study.5 Only 93 of 208 biopsy 
samples were of adequate quality and obtained 
within 5 days after randomization; the overall 
rate of alcoholic steatohepatitis on histologic 
analysis was 88%. This rate rose to 91% in cen-
ters where biopsy was routine and fell to 83% 
when the biopsy was performed only on account 
of diagnostic uncertainty. We would advocate 
liver biopsy in situations of clinical uncertainty, 
but future studies that insist on the use of bi-
opsy results may exclude many patients and 
further distance the observations from the rou-
tine clinical management of this florid manifes-
tation of alcoholic liver disease.
DiNubile raises an interesting question re-
garding whether the abrupt cessation of gluco-
corticoids led to an inflammatory reconstitution 
reaction. Such a reaction has not previously been 
recognized in the context of prednisolone treat-
ment of alcoholic hepatitis. The regimen that 
was used reflects the one that is described in 
published studies of prednisolone therapy in al-
coholic hepatitis; to our knowledge, no studies 
have investigated the role of a tapering dose. 
Thus, although we cannot rule out such a reac-
tion, we think that infection and progressive 
liver failure explain most of the catch-up 
mortality after 28 days.
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More on the Age of Transfused Red Cells
To the Editor: The report by Steiner et al. (April 9 
issue)1 concerns one of three recent trials address-
ing the effects of red-cell storage duration on trans-
fusion outcome.2,3 All three trials compared “fresh 
blood,” stored for approximately 7 days, with stor-
age for 2 to 4 weeks and concluded that fresher 
blood afforded no advantage to critically ill adults, 
patients undergoing cardiac surgery, or premature 
infants. These trials reassure us that most pa-
tients receive safe, effective transfusions and will 
not benefit from fresher-than-usual blood. The 
studies do not address storage for 35 to 42 days and 
are not powered to examine certain subpopula-
tions, such as patients with infections. Preclinical 
data suggest that very old blood increases intra-
vascular levels of iron and may present additional 
risk during established infection.4,5 For ethical rea-
sons, clinical trials cannot randomly assign patients 
to receive only the oldest blood, yet units that are 
in the last week of approved storage are trans-
fused daily. Given the absence of need and the 
possible increased risk, we at the National Institutes 
of Health restrict transfusion of very old blood, as 
do the national blood services of the United 
Kingdom and the Netherlands. It is important to 
emphasize these limitations of the clinical trials.
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The authors reply: We agree that the three pub-
lished randomized, controlled trials investigating 
the clinical effects of red-cell storage duration (the 
Red-Cell Storage Duration Study [RECESS],1 the 
Age of Blood Evaluation trial,2 and the Age of 
Red Blood Cells in Premature Infants trial3) were 
not specifically designed to evaluate the oldest 
units — that is, those stored 35 to 42 days. We 
cited this limitation in the Discussion section of 
our report on RECESS. Owing to the clinical 
demand for red-cell units before they reach 35 
days of storage, few participants in RECESS 
received only red-cell units stored this long, and 
these participants may have been a biased subset 
of all study participants.
We also acknowledged in the Discussion sec-
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